Skip to main content
Premium Trial:

Request an Annual Quote

Switch for the Second

France is to announce that individuals under the age of 55 who have received their first dose of AstraZeneca's SARS-CoV-2 vaccine should receive one of the mRNA-based vaccines for their second dose, Reuters reports.

AstraZeneca has run into issues of transparency in its analyses and with reports of side effects with its vaccine. A number of countries, mostly in Europe, paused their rollout of AstraZeneca's vaccine following reports of a rare blood clot side effect. The European Medicines Agency announced, though, that the vaccine is safe and effective and that its benefits outweigh any potential risks, which led some countries to resume administering it.

Some countries like France, though, have advised that the vaccine only be administered to people over the age of 55, Reuters says, noting that the blood clot side effect has mostly occurred in young people. It adds that France is now following in Germany's footsteps to advise that people under 55 who have received one dose of AstraZeneca's SARS-CoV-2 vaccine should receive a different, mRNA-based vaccine for their second dose.

This decision, Reuters notes, is "significant" as mixing and matching of vaccines has not been tested in late-stage clinical trials.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.